drugset / Trial / NCT02917733

A Study of the Absorption, Distribution, Metabolism and Excretion of LY3039478 in Healthy Participants

NCT02917733

Phase 1 Completed 6 enrolled Eli Lilly and Company
NaSingle-groupOpen-labelBasic science

Summary

This type of study is called a radiolabeled study. For this study, LY3039478 (study drug) has been specially prepared to contain radiolabeled carbon \[¹⁴C\]. \[¹⁴C\] is a naturally occurring radioactive form of the element carbon. This study will help determine how the drug appears in the blood, urine, and stool after it is administered by mouth to healthy people. Information about any side effects that may occur will also be collected. This study will last about 10 weeks for each participant.

Timeline

Start
2016-09
Primary completion
2016-11
Completion
2016-11

Drugs

EvaluationDrugModalityDoseRoute
Subject crenigacestat Small molecule Oral

Indications

No indication recorded.